Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PlA(2) polymorphism was not associated with an increased prevalence of coronary artery disease, (OR [95% CI] = 1.07 [0.95-1.21], p = 0.28, pheterogeneity = 0.39).
|
25167197 |
2015 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effect of glycoprotein IIIa PlA2 polymorphism on outcome of patients with stable coronary artery disease and effect of smoking.
|
15194015 |
2004 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Higher prevalence of GPIIIa PlA2 polymorphism in siblings of patients with premature coronary heart disease.
|
10583927 |
1999 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, the frequencies of PLA1 and PLA2 alleles did not differ from those of 388 well-matched control subjects without coronary artery disease.
|
14614355 |
2003 |
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polymorphism of platelet membrane glycoprotein IIIa: human platelet antigen 1b (HPA-1b/PlA2) is an inherited risk factor for premature myocardial infarction in coronary artery disease.
|
9569182 |
1998 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent studies suggest a controversial association between a genetic polymorphism of the glycoprotein IIIa gene (PlA2) and the risk of coronary artery disease.
|
9657436 |
1998 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, the HPA-1b (PlA2) polymorphism of the platelet glycoprotein IIIa has been suggested as a genetic risk factor for coronary artery disease.
|
9282792 |
1997 |
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum type II secretory phospholipase A(2) (sPLA(2)-IIa) has been found to be predictive of adverse outcomes in patients with stable coronary heart disease.
|
21799821 |
2011 |
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several secreted phospholipases A2 (sPLA2s), including group IIA, III, V, and X, have been linked to the development of atherosclerosis, which led to the clinical testing of A-002 (varespladib), a broad sPLA2 inhibitor for the treatment of coronary artery disease.
|
23349189 |
2013 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association of PLA2G2A single nucleotide polymorphisms with type IIa secretory phospholipase A2 level but not its activity in patients with stable coronary heart disease.
|
25794429 |
2015 |
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study confirms a trendwise association of PlA2 with severe coronary artery disease, but rather suggests an even stronger, highly significant association with the metabolic condition of Type 2 diabetes mellitus.
|
12827240 |
2003 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To evaluate the association between glycoprotein IIIa PlA1/PlA2 polymorphism and 1-year cardiovascular events occurrence in aspirin-treated patients with stable coronary artery disease.
|
20739877 |
2010 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We studied the modifier effect of platelet antigen polymorphism (PlA2) on platelet inhibition by acetylsalicylic acid (ASA, i.e., aspirin), clopidogrel, or their combination in patients with coronary heart disease.
|
16458133 |
2006 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Whereas no difference in the distribution of allele and genotype frequencies between controls and survivors of MI could be detected, the PlA2 allele is associated with CHD in low risk patients.
|
9716139 |
1998 |